ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print February 2, 2006
Eur Respir J 2006, doi:10.1183/09031936.06.00110005
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/6/1217    most recent
09031936.06.00110005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van de Garde, E.M.W.
Right arrow Articles by Leufkens, H.G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van de Garde, E.M.W.
Right arrow Articles by Leufkens, H.G.M.


ORIGINAL ARTICLE

ACE-inhibitor use and pneumonia risk in a general, essentially white Caucasian population

E.M.W. van de Garde 1*, P.C. Souverein 2, J.M.M. van den Bosch 3, V.H.M. Deneer 4, H.G.M. Leufkens 2

1 Utrecht Institute of Pharmaceutical Sciences (UIPS), Dept of Pharmacoepidemiology and Pharmacotherapy; and St. Antonius Hospital, Dept of Clinical Pharmacy
2 Utrecht Institute of Pharmaceutical Sciences (UIPS), Dept of Pharmacoepidemiology and Pharmacotherapy
3 St. Antonius Hospital, Dept of Pulmonary Diseases
4 St. Antonius Hospital, Dept of Clinical Pharmacy

* To whom correspondence should be addressed. E-mail: e.m.w.vandegarde{at}pharm.uu.nl.


   Abstract

To assess whether use of ACE-inhibitors is associated with a decreased risk of hospitalization for community-acquired pneumonia (CAP) in a general, essentially white Caucasian population.

Data were obtained from the Dutch PHARMO Record Linkage System. Cases were defined as patients with a first hospital admission for CAP. For each case, up to 4 population controls were matched by age and gender.

The study population comprised 1,108 patients with a first hospital admission for CAP and 3,817 matched controls. After adjusting for several confounders, ACE-inhibitor use was not associated with a decreased incidence of pneumonia (adjusted OR 1.12; 95% CI 0.88 to 1.43). Additionally, no significant association was observed in patients with diabetes, patients with respiratory diseases, patients with heart failure, and patients with both of the last two conditions. Furthermore, adjustment of treatment effects on pneumonia risk using stratification on balancing score also showed no significant association between ACE-inhibitor use and pneumonia risk within the different strata (overall adjusted OR 1.09, 95% CI 0.87 to 1.36).

In contrast to previous findings in Asian populations, we were not able to confirm the beneficial effect of ACE-inhibitors on pneumonia risk in a general, essentially white Caucasian population.

Keywords:  Angiotensin-converting enzyme inhibitor, angiotensin-converting enzyme insertion/deletion polymorphism, pneumonia




This article has been cited by other articles:


Home page
Eur Respir JHome page
S. Teramoto, H. Yamamoto, Y. Yamaguchi, Y. Hanaoka, M. Ishii, S. Hibi, and Y. Ouchi
ACE inhibitors prevent aspiration pneumonia in Asian, but not Caucasian, elderly patients with stroke
Eur. Respir. J., January 1, 2007; 29(1): 218 - 219.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the European Respiratory Society.